Blinatumomab Recombinant Mouse Monoclonal Antibody, Invitrogen™

Descripción

Endotoxin level < 0.01EU/μg by LAL method Use a manual defrost freezer and avoid repeated freeze thaw cycles. Store at 2 to 8 °C for one week. Store at -20 to -80 °C for twelve months from the date of receipt.

Blinatumomab is a BiTE-class (bi-specific T-cell engagers) constructed monoclonal antibody indicated for the treatment of Philadelphia chromosome-negative relapsed or refractory B-cell precursor acute lymphoblastic leukemia (ALL). Blinatumomab is manufactured by Amgen Inc. and marketed under the brand Blincyto™. Blinatumomab was approved in December 2014 under the FDA's accelerated approval program, which allows approval of a pharmaceutical to treat a serious or life-threatening disease based on clinical data showing the pharmaceutical has an effect on a surrogate endpoint reasonably likely to predict clinical benefit to patients.